Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138


Gold Nanoparticles-enabled Efficient Dual Delivery of Anticancer Therapeutics to HeLa Cells.

Farooq MU, Novosad V, Rozhkova EA, Wali H, Ali A, Fateh AA, Neogi PB, Neogi A, Wang Z.

Sci Rep. 2018 Feb 13;8(1):2907. doi: 10.1038/s41598-018-21331-y.


Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.

Brun JL, Rajaonarison J, Nocart N, Hoarau L, Brun S, Garrigue I.

Mol Clin Oncol. 2018 Feb;8(2):227-235. doi: 10.3892/mco.2017.1531. Epub 2017 Dec 8.


Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.

BMJ Open. 2018 Jan 26;8(1):e016700. doi: 10.1136/bmjopen-2017-016700. Erratum in: BMJ Open. 2018 Mar 8;8(3):e016700corr1.


Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.

Jin J, Gkitsas N, Fellowes VS, Ren J, Feldman SA, Hinrichs CS, Stroncek DF, Highfill SL.

J Transl Med. 2018 Jan 24;16(1):13. doi: 10.1186/s12967-018-1384-z.


Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Jeronimo J, Castle PE, Temin S, Denny L, Gupta V, Kim JJ, Luciani S, Murokora D, Ngoma T, Qiao Y, Quinn M, Sankaranarayanan R, Sasieni P, Schmeler KM, Shastri SS.

J Glob Oncol. 2016 Oct 12;3(5):635-657. doi: 10.1200/JGO.2016.006577. eCollection 2017 Oct.


Natural History of HPV Infection across the Lifespan: Role of Viral Latency.

Gravitt PE, Winer RL.

Viruses. 2017 Sep 21;9(10). pii: E267. doi: 10.3390/v9100267. Review.


Immunotherapy for penile cancer.

Buonerba C, Pagliuca M, Vitrone FM, Ascione I, Elefante I, Riccio V, Romano F, De Placido S, Di Lorenzo G.

Future Sci OA. 2017 May 2;3(3):FSO195. doi: 10.4155/fsoa-2017-0031. eCollection 2017 Aug. No abstract available.


Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Bhatia A, Burtness B.

Cancers (Basel). 2017 Aug 31;9(9). pii: E113. doi: 10.3390/cancers9090113. Review.


Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient.

Guo F, Hirth JM, Berenson AB.

J Womens Health (Larchmt). 2017 Oct;26(10):1114-1122. doi: 10.1089/jwh.2017.6424. Epub 2017 Aug 25.


Cervical Precancer Treatment in Low- and Middle-Income Countries: A Technology Overview.

Maza M, Schocken CM, Bergman KL, Randall TC, Cremer ML.

J Glob Oncol. 2016 Aug 17;3(4):400-408. doi: 10.1200/JGO.2016.003731. eCollection 2017 Aug. Review.


Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana.

Yanez RJR, Lamprecht R, Granadillo M, Weber B, Torrens I, Rybicki EP, Hitzeroth II.

PLoS One. 2017 Aug 11;12(8):e0183177. doi: 10.1371/journal.pone.0183177. eCollection 2017.


LALF32-51 -E7, a HPV-16 therapeutic vaccine candidate, forms protein body-like structures when expressed in Nicotiana benthamiana leaves.

Yanez RJR, Lamprecht R, Granadillo M, Torrens I, Arcalís E, Stöger E, Rybicki EP, Hitzeroth II.

Plant Biotechnol J. 2018 Feb;16(2):628-637. doi: 10.1111/pbi.12802. Epub 2017 Sep 7.


Human papillomavirus molecular biology.

Harden ME, Munger K.

Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:3-12. doi: 10.1016/j.mrrev.2016.07.002. Epub 2016 Jul 5. Review.


Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors.

Aguilar R, Johnson JM, Barrett P, Tuohy VK.

J Immunother Cancer. 2017 Apr 18;5:37. doi: 10.1186/s40425-017-0237-2. eCollection 2017.


GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.

Esquerré M, Bouillette-Marussig M, Goubier A, Momot M, Gonindard C, Keller H, Navarro A, Bissery MC.

PLoS One. 2017 Mar 16;12(3):e0174038. doi: 10.1371/journal.pone.0174038. eCollection 2017.


[Epidemiology, prevention and early detection of cervical cancer].

Wentzensen N.

Onkologe (Berl). 2016 Oct;22(10):725-736. doi: 10.1007/s00761-016-0092-7. Epub 2016 Aug 4. Scottish Gaelic.


Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.

Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, Tanton C, Soldan K, Jit M.

Clin Infect Dis. 2017 Mar 1;64(5):580-588. doi: 10.1093/cid/ciw845.


Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.

Kahn JA, Widdice LE, Ding L, Huang B, Brown DR, Franco EL, Bernstein DI.

Clin Infect Dis. 2016 Nov 15;63(10):1281-1287. Epub 2016 Sep 20.


Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.

Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Limson G, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Del Rosario-Raymundo MR, Catteau G, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Int J Cancer. 2016 Dec 15;139(12):2812-2826. doi: 10.1002/ijc.30391. Epub 2016 Sep 9.

Supplemental Content

Support Center